for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Mochida Pharmaceutical Co., Ltd.

4534.T

Latest Trade

4,055.00JPY

Change

5.00(+0.12%)

Volume

43,600

Today's Range

4,030.00

 - 

4,080.00

52 Week Range

3,940.00

 - 

6,110.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Mochida Pharmaceutical Co Completes Share Repurchase

March 18 (Reuters) - Mochida Pharmaceutical Co Ltd <4534.T>::COMPLETES SHARE REPURCHASE.BOUGHT BACK 234,600 SHARES FOR ABOUT 2.5 BILLION YEN THROUGH MARCH 13.

Mochida Pharmaceutical Co Ltd Says To Buy Back Up To 1.26 Percent Of Own Shares Worth 2.5 Billion Yen Through March 22

Mochida Pharmaceutical Co Ltd <4534.T>::MOCHIDA PHARMACEUTICAL CO LTD SAYS TO BUY BACK UP TO 1.26 PERCENT OF OWN SHARES WORTH 2.5 BILLION YEN THROUGH MARCH 22.

Mochida Pharmaceutical to retire treasury shares

Feb 26(Reuters) - Mochida Pharmaceutical Co Ltd <4534.T>:Says it will retire 200,000 shares (0.97 percent of outstanding) of its common stock on March 23.Says the total shares outstanding 20.3 million shares after the retirement.

Mochida Pharmaceutical signs contract for joint development of sale of gout and hyperuricemia treatment FYU-981 in Japan with FUJIYAKUHIN Co., Ltd.

Mochida Pharmaceutical Co Ltd <4534.T>:Says it signed a contract for joint development of sale of gout and hyperuricemia treatment FYU-981 in Japan with FUJIYAKUHIN Co., Ltd..

Mochida Pharmaceutical to retire 465,000 treasury shares

Mochida Pharmaceutical Co Ltd <4534.T>: Says it will retire 465,000 shares (2.2 percent stake) of its common stock on March 23 .Says the total shares outstanding will be 20.5 million shares after the retirement.

Albireo announces submission of new drug application for Elobixibat in Japan

Albireo Pharma Inc <ALBO.O> : Albireo announces submission of new drug application for Elobixibat in Japan .EA Pharma plans to co-market Elobixibat in Japan with Mochida Pharmaceutical Co., Ltd.

Mochida Pharmaceutical gets manufacture and marketing approval for medicine of ulcerative colitis

Mochida Pharmaceutical Co Ltd <4534.T>:Says it received manufacture and marketing approval for a medicine for the treatment of ulcerative colitis.

Mochida Pharmaceutical raises consolidated full-year outlook for FY 2016

Mochida Pharmaceutical Co Ltd:Says the company increased the consolidated full-year outlook for revenue to 92,200 mln yen from 90,000 mln yen for FY ended March 2016.Operating profit forecast increased to 12,100 mln yen from 10,000 mln yen.Ordinary profit forecast increased to 12,300 mln yen from 10,200 mln yen.Net profit forecast increased to 8,100 mln yen from 7,000 mln yen.Earnings per share increased to 407.91 yen from 352.51 yen.Comments increased income from medical products and decreased expenses on R& D are the main reasons for the forecast.

Mochida Pharmaceutical announces agreement on joint development and joint sale of AJG533 in Japan

Mochida Pharmaceutical Co Ltd:Says signed agreement on joint development and joint sale of AJG533 (Elobixibat) a treatment of chronic constipation in Japan, with AJINOMOTO PHARMACEUTICALS CO.,LTD.Says AJG533 ia under development by AJINOMOTO PHARMACEUTICALS CO.,LTD. in Japan.

Mochida Pharmaceutical to retire treasury shares

Mochida Pharmaceutical Co Ltd:To retire 120,000 shares (0.57 pct stake) of its common stock on March 23.Says the total shares outstanding will be 20,980,000 shares after the retirement.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up